Pseudotyped Viruses: A Useful Platform for Pre-Clinical Studies Conducted in a BSL-2 Laboratory Setting by Sofiia N. Rizatdinova, Alina E. Ershova, Irina V. Astrakhantseva

“…In recent years, pseudoviruses, which consist of a backbone of one virus and envelope proteins of another virus, have become one of the most widely used tools for exploring the mechanisms of viruses binding to cells, membrane fusion and viral entry, as well as for screening the libraries of antiviral substances, evaluating the potential of neutralizing monoclonal antibodies, developing neutralization tests, and therapeutic platforms. …”
Get full text

The Importance of CD44 as a Stem Cell Biomarker and Therapeutic Target in Cancer by Ranjeeta Thapa, George D. Wilson

“…Research to date suggests use of monoclonal antibodies against different CD44 variant isoforms and targeted inhibition of HA/CD44-mediated signaling combined with conventional radio/chemotherapy may be the most favorable therapeutic strategy for future treatments of advanced stage malignancies. …”
Get full text

Interleukin-2 receptor β chain as a possible target for low doses of mafosfamide by A. Pukhalsky, A. Toptygina, S. Khaidukov

“…The pretreatment of the suppressor cells with either monoclonal antibodies (mAbs) against the p75 chain of IL-2R, or with Mf abolished the suppressive effect of these cells. …”
Get full text

The emergence of cell-based protein arrays to test for polyspecific off-target binding of antibody therapeutics by Diana M. Norden, Carmen T. Navia, Jonathan T. Sullivan, Benjamin J. Doranz

“…Specificity profiling is a requirement for monoclonal antibodies (mAbs) and antibody-directed biotherapeutics such as CAR-T cells prior to initiating human trials. …”
Get full text

Impact of Thrombopoietin Receptor Agonists on Pathophysiology of Pediatric Immune Thrombocytopenia by Paschalis Evangelidis, Konstantinos Tragiannidis, Eleni Gavriilaki, Athanasios Tragiannidis

“…In these cases, anti-CD20 monoclonal antibodies, such as rituximab and thrombopoietin (TPO) receptor agonists, can be used. …”
Get full text

A Canadian Perspective on Systemic Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma by Anna Spreafico, Eric Winquist, Cheryl Ho, Brian O’Sullivan, Nathaniel Bouganim, Neil Chua, Sarah Doucette, Lillian L. Siu, Desiree Hao

“…The addition of anti-PD-1 monoclonal antibodies to chemotherapy has been shown to extend progression-free survival in recurrent r/m NPC compared to chemotherapy alone; however, approval of PD-1 inhibitors in Canada has lagged behind other jurisdictions where NPC is non-endemic. …”
Get full text

IL-10 in Antilipopolysaccharide Immunity Against Systemic Klebsiella Infections by Tomislav Rukavina, Brigita Ticac, Vanja Vasiljev

“…One group was protected with monoclonal antibodies prior to infection and the second was not. …”
Get full text

Analysis of Progress and Challenges of EGFR-Targeted Molecular Imaging in Cancer With a Focus on Affibody Molecules by Weizhi Chen MD, Baozhong Shen MD, PhD, Xilin Sun PhD

“…In this review, we discuss the recent advances in EGFR-targeted molecular imaging in cancer, with a special focus on the development of imaging agents, including epidermal growth factor (EGF) ligand, monoclonal antibodies, antibody fragments, Affibody, and small molecules. …”
Get full text

Deficiency of Interleukin-1 Receptor Antagonist: A Case with Late Onset Severe Inflammatory Arthritis, Nail Psoriasis with Onychomycosis and Well Responsive to Adalimumab Therapy by Necil Kutukculer, Anne Puel, Sanem Eren Akarcan, Kunihiko Moriya, Neslihan Edeer Karaca, Melanie Migaud, Jean-Laurent Casanova, Guzide Aksu

“…This patient is the first one in the literature with the inflammatory arthritis, nail psoriasis, and onychomycosis and with her remarkable response to monoclonal antibodies. The case responded well and fully recovered after treatment with adalimumab, but not with canakinumab. …”
Get full text

Incidence and Clinical Significance of De Novo Donor Specific Antibodies after Kidney Transplantation by Sophia Lionaki, Konstantinos Panagiotellis, Aliki Iniotaki, John N. Boletis

“…These protocols include removal of the antibodies by plasmapheresis, intravenous administration of immunoglobulin, or depletion of B cells with anti-CD20 monoclonal antibodies along with tacrolimus and mycophenolate mofetil. …”
Get full text

Regulatory T Cells in Autoimmune and Viral Chronic Hepatitis by Pascal Lapierre, Alain Lamarre

“…With the recent advent of monoclonal antibodies able to target regulatory T cells (daclizumab) and improve immune responses and several ongoing clinical trials analysing the impact of regulatory T cell infusion on autoimmune liver disease or liver transplant tolerance, modulation of immunological tolerance through CD4+ regulatory T cells could be a key element of future immunotherapies for several liver diseases allowing restoring the balance between proper immune responses and tolerance.…”
Get full text

Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical Application by Kaichun Li, Jin Li

“…Unfortunately, none of the EGFR targeting antibodies (cetuximab or panitumumab), VEGF targeting monoclonal antibodies (bevacizumab), mTOR inhibitor (everolimus), or HGF/MET pathway targeting drugs has a significant survival benefit. …”
Get full text

The Science of Memory Loss: Insights into Alzheimer’s Disease by Agnieszka Starzyk, Piotr Charzewski

“…Emerging therapies, such as monoclonal antibodies targeting amyloid-beta and tau proteins, show promise but are hindered by challenges in efficacy and safety. …”
Get full text

A Case of Squamous Cell Carcinoma of the Lung That Produced Granulocyte Colony-Stimulating Factor and Interleukin-6 by Nobuhiro Takeuchi, Kento Yamamoto, Kazuyoshi Naba

“…Immunohistochemical examination of biopsy specimens showed positive staining with antigranulocyte colony-stimulating factor and anti-interleukin-6 monoclonal antibodies. Diagnosis of a tumor that produced granulocyte colony-stimulating factor and interleukin-6 was established. …”
Get full text

Update of Immunomodulatory Therapy for Inflammatory Bowel Disease by Charles N Bernstein

“…Newer immunomodulatory agents have been designed for specific targets. and in particular monoclonal antibodies that block the effects of interleukin-1, tumour necrosis factor-alpha and the T cell receptor are available for clinical trials. …”
Get full text

Decoding NAD+ Metabolism in COVID-19: Implications for Immune Modulation and Therapy by Shixu Song, Jialing Gan, Qiuyue Long, Zhancheng Gao, Yali Zheng

“…Current immunotherapies, including IL-6/IL-6R monoclonal antibodies and JAK inhibitors, exhibit suboptimal efficacy, necessitating alternative approaches. …”
Get full text

Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments by Bruno Rafael Ramos de Mattos, Maellin Pereira Gracindo Garcia, Julia Bier Nogueira, Lisiery Negrini Paiatto, Cassia Galdino Albuquerque, Caique Lopes Souza, Luís Gustavo Romani Fernandes, Wirla Maria da Silva Cunha Tamashiro, Patricia Ucelli Simioni

“…Nowadays, advances in treatments for IBD have included biological therapies, based mainly on monoclonal antibodies or fusion proteins, such as anti-TNF drugs. …”
Get full text

The Perspective of Therapeutic Antibody Marketing in Iran: Trend and Estimation by 2025 by Monireh Golpour, Pouya Vatanpour, Mina Amini, Majid Saeedi, Nasim Hafezi, Alireza Rafiei

“…Background. Monoclonal antibodies with high efficiency and specificity are one of the best strategies to diagnose and treat a variety of diseases such as cancer, autoimmunity, and inflammatory diseases. …”
Get full text

Anti-Ebola virus mAb 3A6 protects highly viremic animals from fatal outcome via binding GP(1,2) in a position elevated from the virion membrane by Kathryn M. Hastie, Zhe Li Salie, Zunlong Ke, Peter J. Halfmann, Lisa Evans DeWald, Sara McArdle, Ariadna Grinyó, Edgar Davidson, Sharon L. Schendel, Chitra Hariharan, Michael J. Norris, Xiaoying Yu, Chakravarthy Chennareddy, Xiaoli Xiong, Megan Heinrich, Michael R. Holbrook, Benjamin Doranz, Ian Crozier, Yoshihiro Kawaoka, Luis M. Branco, Jens H. Kuhn, John A. G. Briggs, Gabriella Worwa, Carl W. Davis, Rafi Ahmed, Erica Ollmann Saphire

“…Abstract Monoclonal antibodies (mAbs) against Ebola virus (EBOV) glycoprotein (GP1,2) are the standard of care for Ebola virus disease (EVD). …”
Get full text

Graves’ Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management by Jesús Barrio-Barrio, Alfonso L. Sabater, Elvira Bonet-Farriol, Álvaro Velázquez-Villoria, Juan C. Galofré

“…New treatment modalities such as specific monoclonal antibodies, TSH-R antagonists, and other immunomodulatory agents show a promising outcome for GO patients.…”
Get full text